Oct 2, 2023 08:02AM
Oct 2, 2023 08:00AM
Sep 29, 2023 10:00AM
Sep 29, 2023 10:00AM
Sep 1, 2023 10:05AM
Aug 8, 2023 07:00AM
Jun 30, 2023 12:31PM Horizon Therapeutics (HZNP) Says New Analysis of MRI Findings Shows UPLIZNA Reduced Formation of Subclinical Spinal Cord Lesions in People With NMOSD
Jun 30, 2023 12:30PM
Jun 26, 2023 11:00AM
Jun 26, 2023 11:00AM
Jun 22, 2023 08:02AM
Jun 22, 2023 08:00AM
Jun 17, 2023 05:00PM
Jun 17, 2023 02:00PM New Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials and Real-World Analyses Shed Light on Link Between Thyroid Autoimmunity and Hearing Risks
Jun 12, 2023 08:05AM
Jun 12, 2023 08:00AM
Jun 5, 2023 08:00AM
May 16, 2023 10:54AM
May 15, 2023 09:37PM
May 2, 2023 09:25AM
May 1, 2023 08:00AM Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (
Apr 20, 2023 08:03AM
Apr 20, 2023 08:00AM
Apr 14, 2023 08:16AM
Apr 14, 2023 08:15AM
Apr 10, 2023 08:05AM
Apr 10, 2023 08:00AM
Mar 14, 2023 11:16AM Horizon Therapeutics (HZNP) Announces New Analysis of MRI Findings Show UPLIZNA Reduced Formation of Asymptomatic Optic Nerve Lesions in People With NMOSD
Mar 14, 2023 11:15AM
Mar 13, 2023 05:53AM
Mar 12, 2023 12:00PM
Feb 23, 2023 08:07AM
Feb 23, 2023 08:00AM
Jan 18, 2023 08:03AM
Jan 18, 2023 08:00AM Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Pri
Dec 20, 2022 08:02AM
Dec 20, 2022 08:00AM
Dec 12, 2022 06:00AM
Nov 30, 2022 10:39AM
Nov 23, 2022 06:03AM
Nov 23, 2022 06:00AM
Nov 16, 2022 08:15AM Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
Nov 2, 2022 07:00AM
Oct 26, 2022 08:00AM
Oct 26, 2022 08:00AM
Oct 24, 2022 05:58AM
Oct 22, 2022 10:30AM
Oct 13, 2022 08:00AM
Oct 12, 2022 08:00AM Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022
Sep 29, 2022 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All